3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
10
Metastatic Castration-resistant Prostate Cancer
2
Prostatic Neoplasms, Castration-Resistant
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
30
Nivolumab
30
cabozantinib
20
Ipilimumab
15
Magnetic Resonance Spectroscopy
14
belzutifan
13
lenvatinib
11
Axitinib
9
Specimen Handling
8
Sunitinib
7
durvalumab
5
CTLA-4 Antigen
5
tislelizumab
4
atezolizumab
4
Radiosurgery
4
Interleukin-2
4
Everolimus
4
Biopsy
4
Bevacizumab
4
pazopanib
3
avelumab
3
aldesleukin
3
Immunoglobulin G
3
Disulfides
3
palbociclib
2
fludarabine
2
entinostat
2
adavosertib
2
Surveys and Questionnaires
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Renal Cell
×
Pluvicto
×
Clear all
NCT06964958
2026-02-24
LASER
Dana-Farber Cancer Institute
Phase 2
Active not recruiting
24 enrolled